Breast Cancer Therapeutics Market1
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Global <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong><br />
Market to Focus on Developing<br />
Companion Diagnostics Models, Reports<br />
TMR<br />
Transparency Market Research states in a new report that the<br />
leading players in the global breast cancer therapeutics market<br />
will focus on developing companion diagnostics models to<br />
fortify their presence. As of 2014, the leading players in the<br />
global breast cancer therapeutics market were F.Hoffmann-<br />
LaRocheLtd., Astra Zeneca, and Novartis AG, who held a<br />
whopping share of 93.6%.<br />
Mergers and acquisitions will also shape the trajectory of<br />
progress for the players in the overall market. For instance,<br />
Novartis took over the oncology drug segment of<br />
GlaxoSmithKline in 2015, which will help the company add<br />
another 22 drugs including Tykerb to its pipeline.<br />
The lead author of this research report says, “New product<br />
launches and investments in clinical testing and trials are also<br />
expected to work in the favor of drug breast cancer therapeutics<br />
companies to diversify their portfolio and win bigger shares.”<br />
Increased <strong>Breast</strong> <strong>Cancer</strong> Risk to Pave Way for Steady<br />
Consumption of <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong>
The increasing risk of breast cancer amongst women due to<br />
early onset of menopause, growing pool of geriatric women, and<br />
lifestyle changes are some of the factors driving the breast<br />
cancer therapeutics market. The changes in delayed<br />
childbearing, reproductive patterns, reduced breast feeding,<br />
excessive intake of oral contraceptive pills, and other estrogen<br />
modifying drug therapies are also contributing to the increasing<br />
risks of breast cancer amongst women.<br />
Browse Full Research Report on <strong>Breast</strong> <strong>Cancer</strong><br />
<strong>Therapeutics</strong> Market:<br />
http://www.transparencymarketresearch.com/breast-cancertherapeutics-pipeline-analysis-market.html<br />
The growing problem of obesity is also considered to be a major<br />
factor contributing towards rising cases of breast cancer. The fat<br />
tissues are known to be major producers of estrogen amongst<br />
postmenopausal women. Thus, excess fat and the high<br />
prevalence of obesity is indirectly driving the global breast<br />
cancer therapeutics market.<br />
The growth of domestic pharmaceutical companies that are<br />
making investments to meet the unmet demands of patients by<br />
manufacturing generic drugs as several patented drugs reach<br />
their patient expiration date are expected to boost the market.<br />
Furthermore, this market is also expected to find opportunity in
developing companion diagnostic models that are customized<br />
for specific patients in accordance with the molecular<br />
characteristics of their malignancy.<br />
Entry of Local Manufacturers Could Eat into Revenues of<br />
Branded Drugs<br />
However, the entry of local drug manufacturers has intensified<br />
the competition in the breast cancer therapeutics market. These<br />
manufacturers are offering generic versions of breast cancer<br />
drugs, which is severely impacting the market for branded<br />
drugs. The exorbitant cost of surgeries, radiation therapy, and<br />
chemotherapy also makes it unaffordable for a large number of<br />
patients, especially in the developing regions, where healthcare<br />
infrastructure is poor. All of these factors are expected to hamper<br />
the growth of the breast cancer therapeutics market in the<br />
foreseeable future.<br />
Patent Expiry Drives HER2 Inhibitors Segment as Generic<br />
Drugs will Become Affordable<br />
Currently, North America holds a sizeable share in the global<br />
breast cancer therapeutics market due to supportive insurance
schemes. In the coming years, this regional segment will acquire<br />
a 36.2% share of the overall market revenue. The significant<br />
drug segment in the market will be HER2 inhibitors in the<br />
forecast period as patents near expiration dates, giving entry to<br />
generic drugs. Thus, this drug segment will expand at a CAGR<br />
of 6.2% between 2015 and 2023. Given these positive<br />
developments, the opportunity in the overall market is also<br />
expected to rise to US$16.21 bn by 2023 from US$7.17 bn in<br />
2014, enabling the market to exhibit a CAGR of 8.4% between<br />
2015 and 2023.<br />
Browse Full Press Release on <strong>Breast</strong> <strong>Cancer</strong> <strong>Therapeutics</strong><br />
Market:<br />
Press Release<br />
About Us<br />
Transparency Market Research (TMR) is a global market<br />
intelligence company providing business information reports<br />
and services. The company’s exclusive blend of quantitative<br />
forecasting and trend analysis provides forward-looking insight<br />
for thousands of decision makers. TMR’s experienced team of<br />
analysts, researchers, and consultants use proprietary data<br />
sources and various tools and techniques to gather and analyze<br />
information.
TMR’s data repository is continuously updated and revised by a<br />
team of research experts so that it always reflects the latest<br />
trends and information. With extensive research and analysis<br />
capabilities, Transparency Market Research employs rigorous<br />
primary and secondary research techniques to develop<br />
distinctive data sets and research material for business reports.<br />
Contact Us<br />
Transparency Market Research<br />
State Tower,<br />
90 State Street, Suite 700,<br />
Albany NY - 12207<br />
United States<br />
USA - Canada Toll Free: 866-552-3453<br />
Email: sales@transparencymarketresearch.com<br />
Website: http://www.transparencymarketresearch.com
Change language